Clinical Trial Results with OROS® Hydromorphone

Journal of Pain and Symptom Management

Volumn 33, Issue 2 SUPPL., 2007, Pages

  Wallace, Mark S ^a   Thipphawong, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hydromorphone; low back pain; opioid analgesics; osteoarthritis; pain

Indexed keywords

CODEINE; CYCLOOXYGENASE 2; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OROS; OXYCODONE; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CANCER PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LOW BACK PAIN; MINI MENTAL STATE EXAMINATION; NAUSEA AND VOMITING; OSTEOARTHRITIS; QUALITY OF LIFE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; SOMNOLENCE;

EID: 33846844734     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.09.008     Document Type: Article

References (15)

1. Drover D.R., Angst M.S., Valle M., et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97 (2002) 827-836
2. Angst M.S., Drover D.R., Lötsch J., et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 94 (2001) 63-73
3. Data on file. ALZA Corporation, Mountain View, CA; July 1, 2005.
4. Murray A., and Hagen N.A. Hydromorphone. J Pain Symptom Manage 29 5 Suppl (2005) S57-S66
5. Sarhill N., Walsh D., and Nelson K.A. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 9 (2001) 84-96
6. ® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 23 (2002) 355-368
7. Daut R., Cleeland C., and Flanery R. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17 (1983) 197-210
8. Hanna M. The safety and efficacy of OROS hydromorphone in patients with chronic cancer pain. J Pain 7 Suppl (2006) S35 Abstract 733
9. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
10. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
11. ® hydromorphone in patients with chronic low back pain. Presented at the 11th World Congress on Pain. Sydney, Australia, August 21-26, 2005, Abstract 688-P294:247.
12. Ware J.J., and Sherbourne C.D. The MOS-36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
13. Ware J.E. The MOS 36-Item Short Form Health Survey (SF-36). In: Sederer L., and Dickey B. (Eds). Outcomes assessment in clinical practice (1996), Williams & Wilkins, Baltimore
14. In: Stewart A.L., and Ware J.E. (Eds). Your Sleep. I: Measuring functioning and well-being (1992), Duke University Press, Durham, NC 399-499
15. ® hydromorphone versus extended-release oxycodone for the management of moderate to severe chronic pain in patients with osteoarthritis of the knee or hip, regularly using NSAIDs with or without the addition of opioid analgesia. Presented at the 11th World Congress on Pain. Sydney, Australia, August 21-26, 2005, Abstract 688-P295:247-248.